A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases
Public ClinicalTrials.gov record NCT02633397. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The proposed study is a Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel groups study aimed to evaluate the safety, tolerability and the efficacy of riociguat compared with placebo in patients with sickle cell disease (SCD).
Study identification
- NCT ID
- NCT02633397
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 130 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 10, 2017
- Primary completion
- May 3, 2022
- Completion
- May 3, 2022
- Last update posted
- Jul 18, 2023
2017 – 2022
United States locations
- U.S. sites
- 20
- U.S. states
- 17
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSF Benioff Children's Hospital Oakland | Oakland | California | 94609 | — |
| Howard University | Washington D.C. | District of Columbia | 20060 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Emory University School of Medicine | Atlanta | Georgia | 30329 | — |
| University of Illinois, Chicago | Chicago | Illinois | 60612 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| Tulane University | New Orleans | Louisiana | 70112 | — |
| Johns Hopkins University | Baltimore | Maryland | 21205 | — |
| Boston University Medical Center | Boston | Massachusetts | 02118 | — |
| New York Presbyterian Brooklyn Methodist Hospital | Brooklyn | New York | 11225 | — |
| Albert Einstein University/ Montefiore Medical Center | The Bronx | New York | 10467 | — |
| UNC Comprehensive Sickle Cell Center | Chapel Hill | North Carolina | 27599-7305 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| East Carolina University | Greenville | North Carolina | 27834 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| UPMC Division of Hematology and Oncology | Pittsburgh | Pennsylvania | 15233 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| University of Tennessee Health Science Center | Memphis | Tennessee | 38163 | — |
| University of Texas Southwestern | Dallas | Texas | 75390 | — |
| Virginia Commonwealth University Medical Center | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02633397, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 18, 2023 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02633397 live on ClinicalTrials.gov.